Abeona Therapeutics (ABEO) Competitors $6.59 -0.04 (-0.60%) Closing price 04:00 PM EasternExtended Trading$6.62 +0.03 (+0.38%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ABEO vs. CALT, ELVN, GPCR, CDTX, ARDX, PRAX, PROK, COLL, AKBA, and AMPHShould you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include Calliditas Therapeutics AB (publ) (CALT), Enliven Therapeutics (ELVN), Structure Therapeutics (GPCR), Cidara Therapeutics (CDTX), Ardelyx (ARDX), Praxis Precision Medicines (PRAX), ProKidney (PROK), Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry. Abeona Therapeutics vs. Its Competitors Calliditas Therapeutics AB (publ) Enliven Therapeutics Structure Therapeutics Cidara Therapeutics Ardelyx Praxis Precision Medicines ProKidney Collegium Pharmaceutical Akebia Therapeutics Amphastar Pharmaceuticals Abeona Therapeutics (NASDAQ:ABEO) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations. Does the media refer more to ABEO or CALT? In the previous week, Abeona Therapeutics had 8 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 8 mentions for Abeona Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Abeona Therapeutics' average media sentiment score of 0.17 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Abeona Therapeutics Neutral Calliditas Therapeutics AB (publ) Neutral Is ABEO or CALT more profitable? Abeona Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Abeona Therapeutics' return on equity of -118.82% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Abeona TherapeuticsN/A -118.82% -52.48% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Which has preferable valuation and earnings, ABEO or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Abeona Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbeona Therapeutics$3.50M96.33-$63.73M-$1.27-5.19Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Do analysts recommend ABEO or CALT? Abeona Therapeutics currently has a consensus target price of $19.25, indicating a potential upside of 192.11%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Abeona Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abeona Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders believe in ABEO or CALT? 80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 6.9% of Abeona Therapeutics shares are owned by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, ABEO or CALT? Abeona Therapeutics has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. SummaryAbeona Therapeutics beats Calliditas Therapeutics AB (publ) on 12 of the 16 factors compared between the two stocks. Get Abeona Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABEO vs. The Competition Export to ExcelMetricAbeona TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$339.17M$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E Ratio-5.198.2821.0120.09Price / Sales96.33303.17433.8199.01Price / CashN/A42.5936.1658.27Price / Book6.527.678.125.65Net Income-$63.73M-$55.28M$3.25B$257.91M7 Day Performance14.81%2.50%0.97%2.09%1 Month Performance9.83%11.70%7.36%11.13%1 Year Performance30.75%4.89%31.31%18.40% Abeona Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABEOAbeona Therapeutics3.8465 of 5 stars$6.59-0.6%$19.25+192.1%+22.3%$339.17M$3.50M-5.1990CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ELVNEnliven Therapeutics2.8636 of 5 stars$23.00+2.4%$41.20+79.1%-1.8%$1.13BN/A-11.9850News CoverageGPCRStructure Therapeutics2.9436 of 5 stars$19.57+2.9%$76.17+289.2%-49.1%$1.12BN/A-22.49136CDTXCidara Therapeutics3.6939 of 5 stars$55.32+9.5%$57.29+3.6%+331.6%$1.12B$1.27M-1.8890Positive NewsHigh Trading VolumeARDXArdelyx4.1637 of 5 stars$4.61+2.7%$10.89+136.2%-21.4%$1.10B$333.61M-20.9590Analyst RevisionPRAXPraxis Precision Medicines2.4592 of 5 stars$53.60+6.1%$94.11+75.6%-0.3%$1.09B$8.55M-5.00110News CoverageAnalyst ForecastAnalyst RevisionPROKProKidney3.4049 of 5 stars$3.69-18.7%$5.67+53.6%+53.0%$1.08B$306K-6.153Analyst ForecastGap UpHigh Trading VolumeCOLLCollegium Pharmaceutical4.4186 of 5 stars$32.83+1.0%$43.75+33.3%+1.0%$1.05B$631.45M26.91210Positive NewsAKBAAkebia Therapeutics3.7148 of 5 stars$3.97+1.0%$6.75+70.0%+175.2%$1.04B$160.18M-18.90430AMPHAmphastar Pharmaceuticals4.3171 of 5 stars$21.95+1.3%$32.33+47.3%-45.0%$1.03B$731.97M7.952,028 Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) Alternatives Enliven Therapeutics Alternatives Structure Therapeutics Alternatives Cidara Therapeutics Alternatives Ardelyx Alternatives Praxis Precision Medicines Alternatives ProKidney Alternatives Collegium Pharmaceutical Alternatives Akebia Therapeutics Alternatives Amphastar Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABEO) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABEO Stock Alerts